Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNC and FEC for HER2-negative IBC
NCT01036087Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2010
- Primary completion
- Feb 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT01036087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01036087.